1st drug reduces 'sticky' cholesterol by 65%

The oral drug muvalaplin saw positive results in the first phase 1 study involving health participants for lipoprotein, a genetic marker for cardiovascular disease that's known for "sticky" cholesterol. 

Muvalaplin, a drug under development at Eli Lilly, lowered lipoprotein levels by 65 percent, according to results published Aug. 28 in JAMA

The medication could be the first treatment for lipoprotein, a genetic marker of cholesterol that increases the risk of heart attack and stroke. Lipoprotein is stickier than LDL cholesterol, and drugs indicated for LDL aren't as effective for lipoprotein, meaning muvalaplin has potential to be the first drug to tackle "sticky" cholesterol. 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars